Mode
Text Size
Log in / Sign up
N/A N=33 Treatment

FILtration of Subarachnoid Hemorrhage Via SpinaL CAtheteR Extension

Subarachnoid Hemorrhage

Enrolled (actual)
33
Serious AEs
3.5%
Results posted
Oct 2022
Primary outcome: Primary: Mean Change in Cisternal Blood From Enrollment to Catheter Removal — -64.7 percent change

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Neurapheresis System (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Minnetronix
Primary completion
Jan 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Change in Cisternal Blood From Enrollment to Catheter Removal
-64.7
SECONDARY
Mean Change in Red Blood Cells From Before to After the Treatment Period.
-85.8
SECONDARY
Mean Change in Total Protein From Before to After the Treatment Period
-82.4

Summary

The objective of this study is to further demonstrate safety and characterize effectiveness of the Neurapheresis™ System (extracorporeal system and catheter) to remove red blood cells (RBCs) and lysed blood by-products from hemorrhagic cerebrospinal fluid (CSF) following aneurysmal subarachnoid hemorrhage (aSAH).

Eligibility Criteria

Inclusion Criteria

  • Modified Fisher Grade 2, 3 or 4
  • Hunt & Hess I-IV
  • First aneurysmal SAH
  • Patient is ≤ 48 hours post bleeding event
  • World Federation of Neurosurgeons (WFNS) Grades I-IV

Exclusion Criteria

  • Pregnancy
  • Patients with a SAH due to mycotic aneurysm or AV malformation
  • Patients who present with an acute MI or unstable angina
  • Imaging demonstrates supratentorial mass lesions > or = 15 cc
  • Imaging demonstrates > or = 2 mm of mid-line-shift associated with infarction and or edema
  • Effacement of the basilar cisterns
  • Vasospasm on admission as defined by angiographic evidence
  • Patients with a coagulopathy that cannot be reversed
  • Thrombocytopenia def. platelet count < 100,000
  • Patients on low molecular weight heparin such as Lovenox
  • Non-communicating Obstructive hydrocephalus
  • Existing hardware that prevents accurate CT imaging
  • Pre-existing Lumbar Drain
  • Local skin infections or eruptions over the puncture site
  • Signs of CNS systemic infection, sepsis or pneumonia
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03607825). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search